HLA-G and Immune Evasion in Cancer Cells

Journal of the Formosan Medical Association

Volumn 109, Issue 4, 2010, Pages 248-257

  Sheu, Jim ^a,b,c   Shih, Ie Ming ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cancer; HLA G; immunosurveillance; therapeutics

Indexed keywords

AMINO ACID; CYTOKINE; HLA G ANTIGEN; HORMONE; HYPOXIA INDUCIBLE FACTOR 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOTRANSPLANTATION; ANTIGEN EXPRESSION; BINDING AFFINITY; BLOOD LEVEL; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXON; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEAVY CHAIN; HYPOXIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MOLECULAR MECHANICS; NEOPLASM; PREGNANCY OUTCOME; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRESS; STRUCTURE ANALYSIS; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY; VIRUS INFECTION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNE EVASION; IMMUNOCOMPETENCE; MONITORING, IMMUNOLOGIC; NEOPLASMS;

EID: 77952102491     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60050-2     Document Type: Review

References (68)

1. Kovats S., Main E.K., Librach C., et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248 (1990) 220-223
2. Crisa L., McMaster M.T., Ishii J.K., et al. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 186 (1997) 289-298
3. Singer G., Kurman R.J., McMaster M., et al. HLA-G immuno-reactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 26 (2002) 914-920
4. Rouas-Freiss N., Moreau P., Ferrone S., et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 65 (2005) 10139-10144
5. Kleinberg L., Florenes V.A., Skrede M., et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 449 (2006) 31-39
6. Hansel D.E., Rahman A., Wilentz R.E., et al. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer 35 (2005) 15-23
7. Singer G., Rebmann V., Chen Y.C., et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 9 (2003) 4460-4464
8. Bukur J., Rebmann V., Grosse-Wilde H., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 (2003) 4107-4111
9. Urosevic M., Kurrer M.O., Kamarashev J., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159 (2001) 817-824
10. Wiendl H., Mitsdoerffer M., Hofmeister V., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168 (2002) 4772-4780
11. Amiot L., Le Friec G., Sebti Y., et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 13 (2003) 379-385
12. Rebmann V., Busemann A., Lindemann M., et al. Detection of HLA-G5 secreting cells. Hum Immunol 64 (2003) 1017-1024
13. Rebmann V., Pfeiffer K., Passler M., et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 53 (1999) 14-22
14. Rebmann V., Regel J., Stolke D., et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 13 (2003) 371-377
15. Rebmann V., Switala M., Eue I., et al. Rapid evaluation of soluble HLA-G levels in supernatants of in vitro fertilized embryos. Hum Immunol 68 (2007) 251-258
16. Gros F., Sebti Y., de Guibert S., et al. Soluble HLA-G molecules increase during acute leukemia, especially in sub-types affecting monocytic and lymphoid lineages. Neoplasia 8 (2006) 223-230
17. Gonen-Gross T., Achdout H., Arnon T.I., et al. The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol 175 (2005) 4866-4874
18. Chang C.C., Campoli M., and Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?. Curr Opin Immunol 16 (2004) 644-650
19. Algarra I., Garcia-Lora A., Cabrera T., et al. The selection of tumor variants with altered expression of classical and non-classical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53 (2004) 904-910
20. Zernich D., Purcell A.W., Macdonald W.A., et al. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J Exp Med 200 (2004) 13-24
21. Diehl M., Munz C., Keilholz W., et al. Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol 6 (1996) 305-314
22. Munz C., Stevanovic S., and Rammensee H.G. Peptide presentation and NK inhibition by HLA-G. J Reprod Immunol 43 (1999) 139-155
23. Ishitani A., Sageshima N., Lee N., et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 171 (2003) 1376-1384
24. Park B., Lee S., Kim E., et al. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity 15 (2001) 213-224
25. Yan W.H., and Fan L.A. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res 15 (2005) 176-182
26. Shiroishi M., Kohda D., and Maenaka K. Preparation and crystallization of the disulfide-linked HLA-G dimer. Biochim Biophys Acta 1764 (2006) 985-988
27. Shiroishi M., Kuroki K., Ose T., et al. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 281 (2006) 10439-10447
28. Sheu J.J., and Shih I. Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol 17 (2007) 436-443
29. Rizzo R., Melchiorri L., Stignani M., et al. HLA-G expression is a fundamental prerequisite to pregnancy. Hum Immunol 68 (2007) 244-250
30. Sher G., Keskintepe L., Fisch J.D., et al. Soluble human leukocyte antigen G expression in phase I culture media at 46 hours after fertilization predicts pregnancy and implantation from day 3 embryo transfer. Fertil Steril 83 (2005) 1410-1413
31. Noci I., Fuzzi B., Rizzo R., et al. Embryonic soluble HLA-G as a marker of developmental potential in embryos. Hum Reprod 20 (2005) 138-146
32. Jurisicova A., Casper R.F., MacLusky N.J., et al. HLA-G expression during preimplantation human embryo development. Proc Natl Acad Sci USA 93 (1996) 161-165
33. Pfeiffer K.A., Fimmers R., Engels G., et al. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. Mol Hum Reprod 7 (2001) 373-378
34. Aldrich C.L., Stephenson M.D., Karrison T., et al. HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. Mol Hum Reprod 7 (2001) 1167-1172
35. Creput C., Durrbach A., Menier C., et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39 (2003) 587-594
36. Mouillot G., Marcou C., Rousseau P., et al. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer 113 (2005) 928-936
37. Gazit E., Sherf M., Balbin E., et al. HLA-G expression is induced in Epstein-Barr virus-transformed B-cell lines by culture conditions. Hum Immunol 68 (2007) 463-468
38. Ibrahim E.C., Guerra N., Lacombe M.J., et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61 (2001) 6838-6845
39. Urosevic M., Willers J., Mueller B., et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99 (2002) 609-617
40. Banham A.H., Colonna M., Cella M., et al. Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol 65 (1999) 841-845
41. Colonna M., Navarro F., Bellon T., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186 (1997) 1809-1818
42. Rajagopalan S., and Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189 (1999) 1093-1100
43. Ponte M., Cantoni C., Biassoni R., et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci USA 96 (1999) 5674-5679
44. Cosman D., Fanger N., Borges L., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7 (1997) 273-282
45. Rajagopalan S., Fu J., and Long E.O. Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol 167 (2001) 1877-1881
46. Clements C.S., Kjer-Nielsen L., McCluskey J., et al. Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol 68 (2007) 220-226
47. LeMaoult J., Zafaranloo K., Le Danff C., et al. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19 (2005) 662-664
48. Le Gal F.A., Riteau B., Sedlik C., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11 (1999) 1351-1356
49. Maejima M., Fujii T., Kozuma S., et al. Presence of HLAG-expressing cells modulates the ability of peripheral blood mononuclear cells to release cytokines. Am J Reprod Immunol 38 (1997) 79-82
50. Kanai T., Fujii T., Unno N., et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol 45 (2001) 94-99
51. Kanai T., Fujii T., Kozuma S., et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod 7 (2001) 195-200
52. Contini P., Ghio M., Poggi A., et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33 (2003) 125-134
53. Fournel S., Aguerre-Girr M., Huc X., et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 164 (2000) 6100-6104
54. Solier C., Aguerre-Girr M., Lenfant F., et al. Secretion of proapoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur J Immunol 32 (2002) 3576-3586
55. Naji A., Durrbach A., Carosella E.D., et al. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 68 (2007) 233-239
56. Bahri R., Hirsch F., Josse A., et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176 (2006) 1331-1339
57. LeMaoult J., Krawice-Radanne I., Dausset J., et al. HLAG1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA 101 (2004) 7064-7069
58. Le Rond S., Azema C., Krawice-Radanne I., et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 176 (2006) 3266-3276
59. Ristich V., Liang S., Zhang W., et al. Tolerization of dendritic cells by HLA-G. Eur J Immunol 35 (2005) 1133-1142
60. Sasaki Y., Sakai M., Miyazaki S., et al. Decidual and peripheral blood CD4+ CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 10 (2004) 347-353
61. Navarro F., Llano M., Bellon T., et al. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 29 (1999) 277-283
62. Adrian Cabestre F., Moreau P., Riteau B., et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J Reprod Immunol 43 (1999) 183-193
63. Menier C., Riteau B., Carosella E.D., et al. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 100 (2002) 63-70
64. Braud V.M., Allan D.S., O'Callaghan C.A., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998) 795-799
65. Rajagopalan S., Bryceson Y.T., Kuppusamy S.P., et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 4 (2006) e9
66. Allan D.S., McMichael A.J., and Braud V.M. The ILT family of leukocyte receptors. Immunobiology 202 (2000) 34-41
67. Chang C.C., Ciubotariu R., Manavalan J.S., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237-243
68. Ristich V., Zhang W., Liang S., et al. Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Hum Immunol 68 (2007) 264-271